Chest infection

How England's new lung cancer screening could save thousands of lives – expert Q&A

Retrieved on: 
Thursday, July 13, 2023
People, Smoker, CT, Fatigue, Radiation, Survival, Weight loss, Eye, Cancer, Lung cancer, Scar, Head, Tobacco, Chest infection, Death, Periodic breathing, X-ray, Risk, Smoke, Blood, NHS England, NHS, Environment, Biopsy, Disease, Uranium mining, Dietary supplement, Mobile phone, Medical imaging, Life insurance, Meat, Glass fiber

Lung cancer is often caught too late. As a result, it has one of the lowest survival rates of all cancers. To detect it earlier, NHS England is rolling out a nationwide screening programme that has already begun in some areas, but will ramp up from 2025. Smokers and former smokers aged 55 to 74 will be invited to have their lungs scanned.Why do we need this programme?Two large trials in the US and Europe found it significantly reduced the number of deaths from lung cancer.

Key Points: 


Lung cancer is often caught too late. As a result, it has one of the lowest survival rates of all cancers. To detect it earlier, NHS England is rolling out a nationwide screening programme that has already begun in some areas, but will ramp up from 2025. Smokers and former smokers aged 55 to 74 will be invited to have their lungs scanned.

Why do we need this programme?

    • Two large trials in the US and Europe found it significantly reduced the number of deaths from lung cancer.
    • In some areas of England, lung cancer screening is already being offered, and it is making a huge impact.

How will people be screened?

    • This is a type of CT scan that uses a lower dose of radiation than a regular CT scan.
    • Their head and legs stay outside of the scanner, so they don’t go into a tunnel, which some people worry about.

Who is eligible to be screened?

    • People aged 55 to 74 who smoke tobacco now or who have smoked in the past will be eligible for screening.
    • They will be asked questions about how long they’ve smoked, and any personal or family history of lung diseases or cancer.
    • People at higher risk of lung cancer are more likely to benefit from screening by having lung cancer found early.

What happens if cancer is suspected?

    • Most people will get a screening result showing no signs of lung cancer.
    • But if lung cancer is suspected, the person will be offered more imaging tests and potentially a biopsy to diagnose whether they have lung cancer.

How many people will wrongly be told they might have lung cancer?


    According to the information NHS England uses to invite people to lung screening, seven out of every 250 people screened will have further tests for lung cancer, such as a biopsy, when they do not have lung cancer.

How many people will be told they don’t have lung cancer when they do?


    Like all screening programmes, sometimes screening does not find cancer when it is there. This is not very common in lung cancer screening, but we don’t have very reliable figures because it’s often not reported by trials.

How treatable is lung cancer if it’s caught early?


    Very. An operation is often enough to completely remove the lung cancer or treatment with radiation that can destroy the cancer cells. Around 88% of people diagnosed with lung cancer at the earliest stage (stage one) survive for at least one year and 57% survive for at least five years. However, just 19% of those diagnosed with the latest stage (stage four) survive for one year, and 3% to five years.

Is England the first country to roll out such a programme?


    Lung cancer screening is already happening in several countries, including the US, Croatia, Poland and very soon, Australia. While lung cancer screening has been announced for England, we’re hopeful that similar announcements will be made for Northern Ireland, Scotland and Wales.

How many lives might it save?


    The programme is expected to detect lung cancer in about 9,000 people every year, with most of them found to have early-stage disease – so a lot.

The Inner Circle Acknowledges, Jahaira L. Serrano, MD, FACCP, as a Pinnacle Life Achiever for her contributions to the medical field

Retrieved on: 
Wednesday, May 3, 2023
COPD, DOS, Asthma, Pneumonia, University, Emphysema, NBPS, Pharynx, Education, University of Puerto Rico School of Dental Medicine, Service, Physician, COVID-19, Chest infection, Diagram, Respiratory system, Multimedia, Mentorship, Mortality, Lung, Pulmonology, Inner circle, Nose, Suite, University of Puerto Rico School of Medicine, Patient, National Board of Medical Examiners, Internal medicine, American College of Chest Physicians, Histology, Chronic obstructive pulmonary disease, American College, Ministry of Health (New Zealand), Medical degree, Nursing, Incidence, Science, MD, Surgeon, Biology, Medicine

ARECIBO, Puerto Rico, May 3, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Jahaira L. Serrano, MD, FACCP, is acknowledged as a Pinnacle Life Achiever for her contributions to the medical field.

Key Points: 
  • ARECIBO, Puerto Rico, May 3, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Jahaira L. Serrano, MD, FACCP, is acknowledged as a Pinnacle Life Achiever for her contributions to the medical field.
  • Dr. Serrano began her educational pathway at the University of Puerto Rico in Cayey where she earned a Bachelor of Science in Biology.
  • She then attended the University of Puerto Rico School of Medicine in 2002 where she completed a Medical Degree in 2002.
  • According to Dr. Serrano, the NBPS provides continuing board certification for DOs and MDs who uphold medical education and patient care standards.

Cystic Fibrosis Therapeutics Market Report 2023: Advancements in R&D Progress Bolsters Sector - ResearchAndMarkets.com

Retrieved on: 
Friday, January 20, 2023
Medical Devices, Health, Stem Cells, Physical Therapy, Managed Care, Pharmaceutical, Distribution (marketing), Liver, Administration, Route of administration, Mucus, Chest infection, Upper respiratory tract infection, CF, Pulmonary function testing, IRT, Agent handling, Route, Medication, Patient, Inflammation, Chest pain, Project delivery method, Research, Gland, Pharmacy, Therapy, CFTR, Sodium, Inhalation, Gastrointestinal tract, Pancreas, Disease, US, Genetic, Medical device, Feces, Blood pressure, Dietary supplement, Pharmaceutical industry, Others, Growth, Perspiration, Cystic fibrosis, Hospital

Although clinically the least serious problem, increased sodium and chloride concentration in sweat is the undisputed hallmark of cystic fibrosis.

Key Points: 
  • Although clinically the least serious problem, increased sodium and chloride concentration in sweat is the undisputed hallmark of cystic fibrosis.
  • The outlook for cystic fibrosis has improved considerably in recent five years due to advancements in R&D of treatment, although most people with cystic fibrosis will have shorter-than-average life assurance.
  • On the Test Type segment, the Global Cystic Fibrosis Therapeutics Market has been differentiated into Pulmonary Function, Sweat, IRT, Fecal, and Genetic.
  • In addition, advanced experimental approaches have been established to accelerate the development of novel modulators, effectively boosting the Cystic Fibrosis Therapeutics Market.

Jahaira L. Serrano, MD is recognized by Continental Who's Who

Retrieved on: 
Friday, January 6, 2023
Mentorship, COPD, Medical degree, American College, Diagram, Lung, Physician, Internal medicine, COVID-19, NBPS, Histology, Respiratory system, Multimedia, University of Puerto Rico School of Dental Medicine, Suite, Mortality, Pulmonology, Ministry of Health (New South Wales), Patient, American College of Chest Physicians, Private practice, Pneumonia, Nose, DOS, University, Pharynx, National Board of Medical Examiners, Respiratory disease, Asthma, Chest infection, Degenerative disease, Service, Continental, Chronic obstructive pulmonary disease, University of Puerto Rico School of Medicine, Medical device, Surgeon, Incidence, MD, Science, Medicine, Biology

ARECIBO, Puerto Rico, Jan. 6, 2023 /PRNewswire/ -- Jahaira L. Serrano, MD, FACCP, is being recognized by Continental Who's Who as a Distinguished Healthcare Provider in the medical field and for her contributions at Serrano Pulmonary Services.

Key Points: 
  • ARECIBO, Puerto Rico, Jan. 6, 2023 /PRNewswire/ -- Jahaira L. Serrano, MD, FACCP, is being recognized by Continental Who's Who as a Distinguished Healthcare Provider in the medical field and for her contributions at Serrano Pulmonary Services.
  • Dr. Serrano completed an Internal Medicine residency in 2005 and Pulmonary Medicine Fellowship in 2007, both at the University of Puerto Rico University District Hospital.
  • Dr. Serrano treats patients at Serrano Pulmonary Services, located at 702 Ave San Luis, Suite 129 in Arecibo, Puerto Rico.
  • Dr. Serrano would like to dedicate this honor to her mother, Mrs. Maria Dominguez, and her mentors, Ruth Santos, MD, and Yohana de Jesús, MD.

Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease

Retrieved on: 
Monday, October 17, 2022
U.S. Securities and Exchange Commission, Respiratory disease, Chronic cough, Communication, Therapy, Bronchiectasis, Osteogenesis imperfecta, Review, Annual report, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, Form 6-K, Patient, Neoplasm, Asthma, Monaco Age Oncologie, Security (finance), Program, Enzyme, Inflammation, Partnership, Degenerative disease, R, Lists of diseases, Food, BOS, Company, Ovarian cancer, Marketing, Wheeze, Respiratory tract, GLOBE, Fast Track, Atalanta, OI, Forward-looking statement, Chest infection, FDA, AATD, Biomarker, Pharmaceutical industry, Medical device, EU, Ultragenyx

LONDON, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational oral neutrophil elastase inhibitor, alvelestat (MPH-966). Mereo intends to have an End-of-Phase 2 meeting with the FDA to discuss the design of a registration-enabling study for alvelestat as a treatment for AATD-associated lung disease, including the potential opportunity for an accelerated approval pathway, around the end of the year.

Key Points: 
  • We are grateful to the FDA for granting us Fast Track designation, and for their recognition of alvelestat as a potentially first-in-class oral neutrophil elastase inhibitor.
  • AATD is a rare, genetic disease that results in a deficiency of the alpha-1 antitrypsin protein, which protects the lungs against damaging enzymes that the body releases during inflammation.
  • In May 2022, Mereo reported positive top-line safety and efficacy data from the ASTRAEUS Phase 2 study of alvelestat in severe AATD-associated emphysema.
  • The Company has two rare disease product candidates, setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe Alpha-1 antitrypsin deficiency (AATD) and Bronchiolitis Obliterans Syndrome (BOS).

Jahaira L. Serrano, MD, FACCP, is recognized by Continental Who's Who

Retrieved on: 
Monday, August 29, 2022
Lung, Respiratory disease, Mortality, Patient, COVID-19, University, Private practice, Ministry of Health (New South Wales), Mentorship, Continental, DOS, University of Puerto Rico School of Dental Medicine, Research, Physician, Chest infection, Internal medicine, View, Pharynx, University of Puerto Rico School of Medicine, Nose, Degenerative disease, Pneumonia, Sex, Suite, Medicine, Diagram, Respiratory system, Asthma, Chronic obstructive pulmonary disease, American College, Education, Multimedia, Histology, COPD, NBPS, National Board of Medical Examiners, American College of Chest Physicians, Pulmonology, Service, Medical device, Science, Biology, Incidence, MD, Surgeon

Dr. Serrano began her education by earning a Bachelor of Science in Biology from the University of Puerto Rico in Cayey.

Key Points: 
  • Dr. Serrano began her education by earning a Bachelor of Science in Biology from the University of Puerto Rico in Cayey.
  • She earned her Medical Degree at the University Of Puerto Rico School Of Medicine in 2002.
  • The doctor is board-certified in Internal Medicine and Pulmonary Medicine by the National Board of Physicians and Surgeons (NBPS).
  • She was recognized with profile features in Issue Wire and Health News Today for her outstanding work.

Jahaira L. Serrano, MD, FACCP is recognized by Continental Who's Who

Retrieved on: 
Wednesday, April 13, 2022
Chronic obstructive pulmonary disease, NBPS, University of Puerto Rico School of Medicine, COPD, COVID-19, Nose, Asthma, University of Puerto Rico School of Dental Medicine, Research, Mortality, Medicine, Service, Ministry of Health (New South Wales), Continental, Degenerative disease, Respiratory disease, Education, Pulmonology, Patient, Histology, Lung, Pharynx, DOS, Private practice, Respiratory system, Sex, American College, Mentorship, Medical school, American College of Chest Physicians, Chest infection, Pneumonia, Multimedia, University, Physician, Diagram, View, National Board of Medical Examiners, Internal medicine, Medical device, Biology, MD, Science, Surgeon, Incidence

ARECIBO, Puerto Rico, April 13, 2022 /PRNewswire/ -- Jahaira L. Serrano, MD, FACCP, is being recognized by Continental Who's Who as a Top Pinnacle Lifetime Achiever in the Medical field and in acknowledgment of her work at Serrano Pulmonary Services.

Key Points: 
  • ARECIBO, Puerto Rico, April 13, 2022 /PRNewswire/ -- Jahaira L. Serrano, MD, FACCP, is being recognized by Continental Who's Who as a Top Pinnacle Lifetime Achiever in the Medical field and in acknowledgment of her work at Serrano Pulmonary Services.
  • Dr. Serrano began her education by earning a Bachelor of Science in Biology from the University of Puerto Rico in Cayey.
  • She earned her Medical Degree at the University of Puerto Rico - School of Medicine in 2002.
  • The doctor is board-certified in Internal Medicine and Pulmonary Medicine by the National Board of Physicians and Surgeons (NBPS).

Evercare Group launches Evercare Foundation to help bridge the gap in inequality in healthcare

Retrieved on: 
Tuesday, March 15, 2022
Goal, Adolescence, Down syndrome, Time, Solution, Hospital, Economic development, Immunization, Health, Patient, Egypt Economic Development Conference, Breast, Investment, Degenerative disease, Foundation, Conference, TPG, Social change, Surgeon, World Bank, Chest infection, Caregiver, Low, Group, Family, World, Rehabilitation, Woman, CEO, Evercare Hospital Dhaka, Population, Trauma, Huber loss, Nairobi Women's Hospital, Care Hospitals, Pharmaceutical industry, Healthcare, Medicine

ISLAMABAD, Pakistan, March 15, 2022 /PRNewswire/ -- The Evercare Group today announced the launch of the Evercare Foundation, a non-profit organization working towards equitable health for all and the development of more resilient health systems across the low- and middle-income countries in Africa and South Africa.  

Key Points: 
  • Through focused partnerships and deliberate investments, the Evercare Foundation will continue to build sustainable development across our areas of operation."
  • Through the Evercare Foundation, we aim to focus on communities who have limited or no access to quality healthcare.''
  • The Evercare Foundation is an independent philanthropic organization established to support the impact driven initiatives of the Evercare Group.
  • The Evercare Group believes access to healthcare is a fundamental right and invests in emerging markets to bring private, quality-driven healthcare to meet the needs of local people.

Mereo BioPharma Receives U.S. Orphan Drug Designation for alvelestat in the Treatment of alpha-1 antitrypsin deficiency

Retrieved on: 
Tuesday, October 26, 2021
NCATS, U.S. Securities and Exchange Commission, US FDA, Ovarian cancer, AAT, Life, Liver disease, Marketing, Clinical trial, COVID-19, Inflammation, Bronchiectasis, Program, GLOBE, ODD, Monaco Age Oncologie, Liver, Enzyme, Lung, Security (finance), Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Annual report, Company, BOS, Osteogenesis imperfecta, University of Alabama, Respiratory disease, Asthma, Neoplasm, AATD, OI, Elastin, Degenerative disease, Population, Wheeze, Orphan, Orphan Drug Act of 1983, Orphan drug, University, Patient, NASDAQ, FDA, Lists of diseases, Chronic cough, Time, Adult, Forward-looking statement, Chest infection, Therapy, Form 6-K, Pharmaceutical industry

Mereo is currently developing alvelestat for the treatment of AATD-Lung Disease (AATD-LD).

Key Points: 
  • Mereo is currently developing alvelestat for the treatment of AATD-Lung Disease (AATD-LD).
  • Mereo is conducting a Phase 2 proof-of-concept clinical trial with alvelestat for the treatment of severe alpha-1 antitrypsin deficiency (AATD).
  • By inhibiting NE, Mereo believes alvelestat has the potential to protect AATD patients from further lung damage.
  • In September 2020, the FDA granted Rare Pediatric Disease designation to setrusumab for the treatment of OI.

Global Upper Respiratory Tract Infection Treatment Market to 2024 - Key Drivers, Challenges and Trends - ResearchAndMarkets.com

Retrieved on: 
Monday, September 7, 2020
Health, Infectious diseases, Infectious diseases, Medical specialties, Health, Anatomy, Respiratory tract infection, Respiratory tract, Infection, Upper respiratory tract infection, Chest infection

The "Global Upper Respiratory Tract Infection Treatment Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Upper Respiratory Tract Infection Treatment Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
  • The upper respiratory tract infection treatment market is poised to grow by $ 1.79 billion during 2020-2024 progressing at a CAGR of 3% during the forecast period.
  • The reports on upper respiratory tract infection treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • This study identifies the increasing R&D on upper respiratory tract infection treatment as one of the prime reasons driving the upper respiratory tract infection treatment market growth during the next few years.